BCRX - BioCryst Pharmaceuticals, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

BCRX

BIOCRYST PHARMACEUTICALS, INC.

NASDAQ

$8.40

▲ UP 5.66% (0.45)

KEY STATISTICS

Market Cap$2.13 B

52w High$11.22

52w Low$6.00

Dividend Yield—

Frequency—

P/E-5.60

Volume5.11M

Shares Out.254.16M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Charles K. Gayer

COMPENSATION 2026

Salary$609,397

Stock Awards$3,358,230

Incentive Plan Pay$749,088

All Other Comp.$17,500

Total$9,627,868

ABOUT

SECTOR

Healthcare

WENT PUBLIC

March 4, 1994

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

435

PRICE TARGET

Target High$29.00

Target Low$11.00

Target Median$17.00

Target Consensus$19.00

UPCOMING EARNINGS

DateNov 2, 2026

DayMonday

Rev. Est.$165.67M

NOV

MON

ETFS HOLDING THIS STOCK

ETFS HOLDING

172

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

52.55%

HOLDERS

454

TOP 8 OF 454 · RANKED BY POSITION SIZE

Ra Capital Management, L.P.

Deerfield Management Company, L.P. (Series C)

15.1M sh

$150.96M

Tcg Crossover Management, LLC

11.0M sh

$110.21M

Perceptive Advisors LLC

10.3M sh

$103.09M

PRICE

$8.40 ▲ UP 5.66% (+$0.45)

About BioCryst Pharmaceuticals, Inc.

https://www.biocryst.com ↗

BioCryst Pharmaceuticals, founded in 1986 in Durham, NC, develops oral small-molecule medicines, including influenza treatments and therapies for hereditary angioedema and other diseases, through collaborations with various biotech and government ...

INDUSTRY

Biotechnology

A PRODUCT BIOCRYST PHARMACEUTICALS, INC. IS KNOWN FOR

ORLADEYO® (berotralstat)

ORLADEYO, BioCryst’s oral, once-daily medication for HAE attack prevention in patients 12 and older, offers a convenient alternative to injections and is being expanded for younger pediatric use.

COMPETITORS

COMPETITOR

BioCryst Pharmaceuticals in 2025

SENTIMENT: + POSITIVE

ACQUISITION · NOVEMBER 2025

BioCryst Pharmaceuticals Announces Definitive Agreement to Acquire Astria Therapeutics, Expanding its HAE Portfolio

BioCryst announced a definitive agreement to acquire Astria Therapeutics, a move described as transformative for the company. This strategic acquisition will add Astria's lead product candidate, navenibart, a long-acting monoclonal antibody for HAE prophylaxis currently in Phase 3 development, to BioCryst's portfolio. The deal is intended to enhance BioCryst's position in the HAE market and drive sustainable growth.

DIVESTITURE · JUNE 2025 · COMPLETED

BioCryst Divests European ORLADEYO Business to Eliminate All Debt and Sharpen Focus on High-Margin Markets

BioCryst Pharmaceuticals sold its European ORLADEYO business to Neopharmed Gentili in a strategic move to exit a breakeven market and fundamentally reshape its capital structure. The proceeds were used to retire all outstanding term debt, significantly improving the company's profitability and financial flexibility moving forward.

Latest News

GLOBENEWSWIRE · OCT 5, 2026

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

—Supports BioCryst's evolution toward a more disciplined R&D model centered on external innovation— RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a Scientific Advisory Board (SAB) comprising seven accomplished scientific and industry leaders with deep expertise across rare disease research and drug development.

READ ARTICLE

EARLIER COVERAGE

DEFENSE WORLD · OCT 2, 2026

BioCryst Pharmaceuticals (NASDAQ:BCRX) and BioXcel Therapeutics (NASDAQ:BTAI) Financial Contrast

BioXcel Therapeutics (NASDAQ: BTAI - Get Free Report) and BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings. Analyst Recommendations This is a breakdown of current

READ ARTICLE